Table 4.

Adverse events up to one year: ranibizumab vs. control

Ocular adverse event*	0.3 mg ranibizumab n = 196	0.5 mg ranibizumab n = 201	All doses ranibizumab n = 397	Control n = 206	RR [95% CI] All doses vs. control
Endophthalmitis	0	2 (< 1%)	2 (< 1%)	0	2.60 [0.13, 53.92]
Retinal detachment	1 (< 1%)	0	1 (< 1%)	1 (< 1%)	0.52 [0.03, 8.25]
Traumatic cataract	18 (9%)	22 (11%)	40 (10%)	14 (7%)	1.48 [0.83, 2.66]
Retinal hemorrhage	2 (1%)	0	2 (< 1%)	2 (< 1%)	0.52 [0.07, 3.66]
Vitreous hemorrhage	1 (< 1%)	0	1 (< 1%)	0	1.56 [0.06, 38.13]
Uveitis	0	1 (< 1%)	1 (< 1%)	0	1.56 [0.06, 38.13]
Elevated intraocular pressure (30 mmHg or more increase)	13 (7%)	17 (8%)	30 (8%)	7 (3%)	2.22 [0.99, 4.98]
Ocular inflammation (trace to 4+)	21 (11%)	26 (13%)	47 (12%)	9 (4%)	2.71 [1.36, 5.42]

Non-ocular adverse event*	0.3 mg ranibizumab n = 196	0.5 mg ranibizumab n = 201	All doses ranibizumab n = 397	Control n = 206	RR [95% CI] All doses vs. control
Death	3 (2%)	2 (<1%)	5 (1%)	2 (< 1%)	1.30 [0.25, 6.63]
Myocardial infarction	1 (< 1%)	3 (1%)	4 (1%)	1 (< 1%)	2.08 [0.23, 18.45]
Stroke or cerebral infarction	1 (< 1%)	1 (< 1%)	2 (< 1%)	1 (< 1%)	1.04 [0.09, 11.38]
Ischemic cardiomyopathy	0	0	0	1 (< 1%)	0.17 [0.01, 4.24]
Treatment-emergent hypertension	7 (4%)	15 (7%)	22 (6%)	17 (8%)	0.67 [0.36, 1.24]
Non-ocular hemorrhage	9 (5%)	13 (6%)	22 (6%)	6 (3%)	1.90 [0.78, 4.62]

CI: confidence interval

RR: risk ratio

^*Adverse events experienced by 420 participants in the ANCHOR 2006 study and 183 participants in the PIER 2008 study. Adverse events at one-year follow up not reported in MARINA 2006.